Evaluation of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 levels in gingival fibroblasts of cyclosporin A-treated patients

Journal of Periodontology

Volumn 73, Issue 11, 2002, Pages 1273-1278

  Tüter, Gülay ^a   Serdar, Muhuttin A ^b   Yalim, Mehmet ^a   Gürhan, Ismet S ^c   Baloş, Köksal ^a  

^a GAZI UNIVERSITY   (Turkey)

^b GULHANE SCHOOL OF MEDICINE   (Turkey)

^c EGE UNIVERSITY   (Turkey)

Author keywords

Cyclosporin A adverse effects; Gingival hyperplasia pathogenesis; Matrix metalloproteinase tissue inhibitors; Matrix metalloproteinases

Indexed keywords

ANTIBIOTIC AGENT; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; INTERSTITIAL COLLAGENASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADULT; ARTICLE; CELL GROWTH; CELL LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EVALUATION; EXPLANT; FEMALE; FIBROBLAST; FIBROBLAST CULTURE; GINGIVA; GINGIVA OVERGROWTH; HUMAN; HUMAN CELL; HYPERTENSION; HYPERTRICHOSIS; KIDNEY GRAFT; LIVER TOXICITY; MALE; NEPHROTOXICITY; NEUROTOXICITY; PATHOGENESIS; SAMPLE; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; THROMBOEMBOLISM;

ADULT; CASE-CONTROL STUDIES; CELLS, CULTURED; CYCLOSPORINE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLASTS; GINGIVA; GINGIVAL OVERGROWTH; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MATRIX METALLOPROTEINASE 1; MIDDLE AGED; STATISTICS, NONPARAMETRIC; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 0036866498     PISSN: 00223492     EISSN: None     Source Type: Journal    
DOI: 10.1902/jop.2002.73.11.1273     Document Type: Article

References (47)

1. Schreiber SL. Chemistry and biology of the immunophilins and their immunosuppressive ligands. Science 1991;251:283-287.
2. Faulds D, Goa KL, Benfield P, et al. Cyclosporin A: Review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in immunoregulatory disorders. Drugs 1993;5:953-1040.
3. Pernu HE, Pernu LM, Huttunen KR, Nieminen PA, Knuuttila AM. Gingival overgrowth among renal transplant recipients related to immunosuppressive medication and possible local background factors. J Periodontol 1992;63: 548-553.
4. Marshall RI, Bartold PM. Medication induced gingival overgrowth. Oral Dis 1998;4:130-151.
5. Kantarci A, Cebeci I, Tuncer O, Carin M, Firatli E. Clinical effects of periodontal therapy on the severity of cyclosporin A-induced gingival hyperplasia. J Periodontol 1999;70:587-593.
6. Birkedal-Hansen H. Role of matrix metalloproteinases in human periodontal disease. J Periodontol 1993;64:474-484.
7. Westerlund U, Ingman T, Lukinmaa P-L, et al. Human neutrophil gelatinase and associated lipokalin in adult and localized juvenile periodontitis. J Dent Res 1996;75:1553-1563.
8. Aiba T, Akeno N, Kawane T, Okamoto H, Horiuchi N. Matrix metalloproteinases-1 and -8 and TIMP-1 mRNA levels in normal and diseased human gingivae. Eur J Oral Sci 1996;104:562-569.
9. Meikle MC, Hembry RM, Holley J, Horton C, McFarlane CG, Reynolds JJ. Immunolocalization of matrix metalloproteinases and TIMP-1 in human gingival tissue from periodontitis patients. J Periodont Res 1994;29:118-126.
10. Kubota T, Nomura T, Takahashi T, Hara K. Expression of mRNA for matrix metalloproteinases and tissue inhibitors of metalloproteinases in periodontitis-affected human gingival tissue. Arch Oral Biol 1996;41:253-262.
11. Williamson MS, Miller EK, Plemons J, Rees T, Iacopino AM. Cyclosporin A upregulates interleukin-6 gene expression in human gingiva: Possible mechanism for gingival overgrowth. J Periodontol 1994;65:895-903.
12. Nares S, Ng MC, Dill RE, Park B, Cutler CW, Iacopino AM. Cyclosporin A upregulates platelet-derived growth factor-B chain in hyperplastic human gingiva. J Periodontol 1996;67:271-278.
13. Plemons JM, Dill RE, Rees TD, Dyer BJ, Ng MC, Iacopino AM. PDGF-B producing cells and PDGF-B gene expression in normal gingiva and cyclosporin A-induced gingival overgrowth. J Periodontol 1996;67:264-270.
14. Ayanoglou CM, Lesty C. Cyclosporin A induced gingival overgrowth in the rat: A histological, ultrastructural and histomorphometric evaluation. J Periodont Res 1999;34:7-15.
15. Mariani G, Calastrini C, Carinci F, Bergamini L, Calastrini F, Stabelini G. Ultrastructural and histochemical features of the ground substance in cyclosporin A induced gingival overgrowth. J Periodontol 1996;67:21-27.
16. Ono M, Hatamochi A, Arakawa M, Ueki H. Effects of cyclosporin A on cell proliferation and collagen production by human skin fibroblasts. J Dermatol Sci 1991; 2:274-280.
17. Willershausen-Zonnchen B, Lemmen C, Schumacher U. Influence of cyclosporin A on growth and extracellular matrix synthesis of human fibroblasts. J Cell Physiol 1992;152:397-402.
18. Silness J, Löe H. Periodontal disease in pregnancy. II. Correlation between oral hygiene and oral condition. Acta Odontol Scand 1964;22:121-135.
19. Löe H. The gingival index, plaque index and the retention index systems. J Periodontol 1967;38:610-616.
20. Angelopoulos AP, Goaz BS. Incidence of diphenylhydantoin gingival hyperplasia. J Oral Surg 1972;34:898-906.
21. Coletta RD, Almeida OP, Graner E, Page RC, Bozzo L. Differential proliferation of fibroblasts cultured from hereditary gingival fibromatosis and normal gingiva. J Periodont Res 1998;33:1-7.
22. Bartold PM. Cyclosporin and gingival overgrowth. J Oral Pathol 1987;16:463-468.
23. Daley TD, Wysocki GP. Cyclosporin therapy. Its significance to the periodontist. J Periodontol 1984;55:708-712.
24. Bartold PM. Turnover in periodontal connective tissues; dynamic homeostasis of cells, collagen and ground substance. Oral Dis 1995;1:238-253.
25. Woessner JF. The family of matrix metalloproteinases. Ann N Y Acad Sci 1994;732:11-21.
26. Birkedal-Hansen H. From tadpole collagenase to family of matrix metalloproteinases. J Oral Pathol 1988;17: 445-451.
27. Mariotti A, Hassel T, Jacobs D, Manning CJ, Hefti AF. Cyclosporin A and hydroxycyclosporine (M-17) affect the secretory phenotype of human gingival fibroblasts. J Oral Pathol Med 1998;27:260-266.
28. Hempelmann U, Haag-Weber M, Horl WH, Tschesche H. Effect of immunosuppressive drugs on the release of metalloproteinases from human PMNL. Transpl Int 1991; 4:26-30.
29. Thomason JM, Sloan P, Seymour RA. Immunolocalization of collagenase (MMP-1) and stromelysin (MMP-3) in the gingival tissues of organ transplant patients medicated with cyclosporin. J Clin Periodontol 1998;25:554-560.
30. 4 and platelet activating factor in gingival crevicular fluid in renal transplant patients receiving cyclosporin A. J Periodontol 2000;71:50-57.
31. Tipton D, Dabbous MK. Dose-dependent collagenolytic response profiles in gingival fibroblasts to cyclosporine. J Dent Res 1989;68:361-362.
32. Tipton DA, Pabst MJ, Dabbous MK. IL-1 beta and TNF alpha independent monocyte stimulation of fibroblast collagenase activity. J Cell Biochem 1990;44:253-264.
33. Bolzani G, Coletta RD, Martelli JH, Almeida OP, Graner E. Cyclosporin A inhibits production and activity of matrix metalloproteinases by gingival fibroblasts. J Periodont Res 2000;35:51-58.
34. Sugano N, Ito K, Murai S. Cyclosporin A inhibits collagenase gene expression via AP-1 and JNK suppression in human gingival fibroblasts. J Periodont Res 1998;33: 448-452.
35. Lohi J, Kahari VL, Keski-Oja J. Cyclosporin A enhances cytokine and phorbol ester-induced fibroblast collagenase expression. J Invest Dermatol 1994;102:938-944.
36. Duymelinck C, Deng JT, Dauwe SE, De Broe ME, Verpooten GA. Inhibition of matrix metalloproteinase system in a rat model of chronic cyclosporine nephropathy. Kidney Int 1998;54:804-818.
37. Tipton DA, Stricklin GP, Dabbous MK. Fibroblast heterogeneity in collagenolytic response to cyclosporin. J Cell Biochem 1991;46:152-165.
38. Hassel TM, Cooper GC. Phenytoin induced gingival overgrowth in a mongrel cat model. In: Hassel TM, Johnson MC, Dudley KH, eds. Phenytoin-Induced Teratology and Gingival Pathology. New York: Raven Press; 1980:147-162.
39. Phipps RP, Borrello MA, Blieden TM. Fibroblast heterogeneity in the periodontium and other tissues. J Periodont Res 1997;32:159-165.
40. Seymour RA, Thomason JM, Ellis JS. The pathogenesis of drug induced gingival overgrowth. J Clin Periodontol 1996;23:165-175.
41. Iacopino AM, Doxey D, Cutler CW, et al. Phenytoin and cyclosporine A specifically regulate macrophage phenotype and expression of platelet derived growth factor and interleukin-1 in vitro and in vivo: Possible molecular mechanism of drug induced gingival hyperplasia. J Periodontol 1997;68:73-83.
42. Atilla G, Sorsa T, Ronka H, Emingil G. Matrix metalloproteinases (MMP-8 and -9) and neutrophil elastase in gingival crevicular fluid of cyclosporin treated patients. J Periodontol 2001;72:354-360.
43. Thomason JM, Seymour RA, Ellis JS, et al. Determinants of gingival overgrowth severity in organ transplant patients. An examination of the role of HLA phenotype. J Clin Periodontol 1996;23:628-634.
44. Buduneli N, Kutukculer N, Aksu G, Atilla G. Evaluation of TGF-β1 level in crevicular fluid of cyclosporin A treated patients. J Periodontol 2001;72:526-531.
45. Varga E, Lennon MA, Mair LH. Pre-transplant gingival hyperplasia predicts severe cyclosporine-induced gingival overgrowth in renal transplant patients. J Clin Periodontol 1998;25:225-230.
46. Silva HCCR, Coletta RD, Jorge J, Bolzani G, Almeida OP, Graner E. The effect of cyclosporin A on the activity of matrix metalloproteinases during the healing of rat molar extraction wounds. Arch Oral Biol 2001;46:875-879.
47. Uzel I, Kantarci A, Hong HH, et al. Connective tissue growth factor in drug induced gingival overgrowth. J Periodontol 2001;72:921-931.